Halozyme Therapeutics (HALO)
(Delayed Data from NSDQ)
$64.42 USD
+1.22 (1.93%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $64.96 +0.54 (0.84%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$64.42 USD
+1.22 (1.93%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $64.96 +0.54 (0.84%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth B Momentum C VGM
Zacks News
Alexion-Complement Pharma Tie Up to Treat Neuro Disorders
by Zacks Equity Research
Alexion (ALXN) teams up with Complement Pharma to co-develop its C6 inhibitor, CP010, for neurodegenerative disorders.
Options Traders Expect Huge Moves in Halozyme Therapeutics (HALO) Stock
by Zacks Equity Research
Halozyme Therapeutics (HALO) needs investors to pay close attention to the stock based on moves in the options market lately.
Bristol-Myers Yervoy Gets Positive CHMP Opinion for Melanoma
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) immuno-oncology drug Yervoy gets positive opinion from the CHMP of the European Medicines Agency for the treatment of pediatric patients of 12 years and older with unresectable or metastatic melanoma.
Bristol-Myers' Opdivo/Yervoy sBLA for RCC Accepted by FDA
by Zacks Equity Research
Bristol-Myers (BMY) supplemental Biologics License Application (sBLA) for Opdivo and Yervoy combination for the treatment of intermediate- and poor-risk patients with advanced renal cell carcinoma was accepted by the FDA.
The Zacks Analyst Blog Highlights: Halozyme Therapeutics, Protagonist Therapeutics, Aptose Biosciences and Pieris Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Halozyme Therapeutics, Protagonist Therapeutics, Aptose Biosciences and Pieris Pharmaceuticals
Why Halozyme Therapeutics (HALO) Could Be Positioned for a Surge
by Zacks Equity Research
Halozyme Therapeutics (HALO) is seeing solid earnings estimate revisions, and the stock is showing decent short-term momentum as well.
4 Top-Ranked Biotech Stocks Under $20 With Room for Growth
by Zacks Equity Research
We take a look at the biotech stocks with a potential for growth keeping in mind that the industry has witnessed a rebound in 2017 from last year's challenges.
Bristol-Myers (BMY) Reports Positive Data on Leukemia Drug
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced positive data from an ongoing phase II study on leukemia drug Sprycel in addition to a chemotherapy regimen modelled on a Berlin-Frankfurt-Munster high-risk backbone for two years.
Options Traders Expect Huge Moves in Halozyme Therapeutics (HALO) Stock
by Zacks Equity Research
Investors in Halozyme Therapeutics (HALO) need to pay close attention to the stock based on moves in the options market lately.
Implied Volatility Surging for Halozyme Therapeutics (HALO) Stock Options
by Zacks Equity Research
Surging implied volatility makes Halozyme Therapeutics (HALO) stock lucrative to the option traders.
Should You Buy Halozyme Therapeutics (HALO) Ahead of Earnings?
by Zacks Equity Research
Halozyme Therapeutics (HALO) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Can Halozyme (HALO) Run Higher on Strong Earnings Estimate Revisions?
by Zacks Equity Research
Halozyme Therapeutics (HALO) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision.
Bristol-Myers (BMY) Collaborates With Halozyme for ENHANZE
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) enters into a collaboration and license agreement with Halozyme Therapeutics, Inc. (HALO).
Strength Seen in Halozyme Therapeutics (HALO): Stock Soars 21.2%
by Zacks Equity Research
Halozyme Therapeutics (HALO) was a big mover last session, as the company saw its shares rise more than 21% on the day amid huge volumes.
Roche's (RHHBY) Combination Cancer Remedy Wins FDA Approval
by Zacks Equity Research
Roche (RHHBY) announced that the FDA has granted approval to the subcutaneous injection of its marketed lymphoma drug MabThera/Rituxan as Rituxan Hycela for the treatment of adults with different types of blood cancers.
Why Halozyme Therapeutics (HALO) Might Surprise This Earnings Season
by Zacks Equity Research
Halozyme Therapeutics (HALO) could be an interesting stock for investors ahead of earnings, as it has a positive ESP and a favorable Zacks Rank.
Halozyme Therapeutics (HALO) in Focus: Stock Up 6.4%
by Zacks Equity Research
Halozyme Therapeutics, Inc. (HALO) saw its shares rise above 6% in the last trading session.
Can the Rally in Halozyme (HALO) Shares Continue?
by Zacks Equity Research
Halozyme Therapeutics, Inc. (HALO) has been on the move lately as the stock has risen by 15.1% in the past four weeks, and it is currently trading well above its 20-Day SMA.
Halozyme Therapeutics (HALO) Worth a Look: Stock Up 18%
by Zacks Equity Research
Halozyme Therapeutics, Inc. (HALO) shares rose almost 18% in the last trading session.
Halozyme (HALO) Up on Positive Phase II Data on PEGPH20
by Zacks Equity Research
Halozyme (HALO) announced top-line data from the combined analysis from its phase II HALO 202 study on PEGPH20.